Vanda Pharmaceuticals Inc
VNDA
Get informed when a big investor buys or sells
+ FollowMarket Cap$317.52M
Close$
$-3.37
162% downside
Current Fair Value
162% downsideOvervalued by 162% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $317.52 Million |
|---|---|
| Enterprise Value | $261.63 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.74 |
| Beta | 0.64 |
| Outstanding Shares | 60,226,570 |
Return
| Return on Equity | -124.83% |
|---|---|
| Return on Assets | -66.64% |
| Return on Invested Capital | -74.14% |
Valuation & Multiples
| P/E Ratio | -1.14 |
|---|---|
| PEG | -0.88 |
| Price to Sales | 1.81 |
| Price to Book Ratio | 1.81 |
| Enterprise Value to Revenue | 1.21 |
| Enterprise Value to EBIT | -1.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$61.92 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.72
Average shareholder expectationRevenue Estimate
$69.30 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3572▲ 7.55% |
|---|---|
| Total Calls | 167,400▼ 59.96% |
| Total Puts | 59,800▼ 49.24% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 84.64%▲ 6.42% |
|---|---|
| Total Invested | $308.75M▼ 3.34% |
| Investors Holding | 176▲ 1.00% |
ESG Score
No data
About Vanda Pharmaceuticals Inc
CEO: Mihael Polymeropoulos Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.